Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of VB19055 in uncontrolled or resistant hypertension
CTR20262790Phase 2Active
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VB19055 in hypertension (HTN), resistant hypertension (RH), sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd.. Started Jul 2026; status: active.
02
Drugs
VB19055
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20262790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262790.